Please login to the form below

Not currently logged in
Email:
Password:

GSK buys Shenzhen Neptunus stake

GSK is set to become the sole owner of joint venture company Shenzhen GSK-Neptunus Biologicals

GlaxoSmithKline (GSK) has entered into an agreement to acquire the remaining 51 per cent stake of Shenzhen Neptunus Interlong Bio-Technique Co in the joint venture (JV) company, Shenzhen GSK-Neptunus Biologicals Co (GSKNB), for £24m ($39m) in cash. 

Established in June 2009, the GSKNB alliance focuses on the development and manufacture of seasonal and pandemic influenza vaccines for China, Hong Kong and Macau. GSK increased its share from 40 per cent to 49 per cent in August 2010.

Jean Stephenne, chairman and president GSK Biologicals, said: "The decision to acquire the remaining equity interest in GSKNB reflects the importance GSK places in expanding our product offering in China and making new vaccines available to improve public health in this fast growing emerging market. GSKNB employees have made good progress preparing the site for the production of influenza vaccines and we look forward to continuing this work."

After approval of this agreement by the Peoples Republic of China's authorities, GSK will become the sole owner of GSKNB. 

14th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics